Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02187029 · ClinicalTrials.gov registry record · Phase 1
Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02187029 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 30 participants.
The verdict
NCT02187029, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the effect of PF-06743649 in lowering serum uric acid in subjects suffering from gout following 14 days of dosing, as well as assessing safety and tolerability.
Interventions
- OTHER Placebo
- DRUG PF-06743649
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-07 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02187029
The ClinicalTrials.gov registry entry for NCT02187029 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02187029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02187029 about?
NCT02187029 is a clinical study titled "Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.". The purpose of the study is to assess the effect of PF-06743649 in lowering serum uric acid in subjects suffering from gout following 14 days of dosing, as well as assessing safety and tolerability.
What is the current status of trial NCT02187029?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-07. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02187029?
The interventions under investigation include: Placebo (OTHER), PF-06743649 (DRUG).
Who is sponsoring clinical trial NCT02187029?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.